qRT-PCR demonstrated an induction in DRAK2 expression (Figure 4A; mean 2.5-fold increase, P=0.01) in tumour from each of the patients treated with rofecoxib, reflective of the changes seen with COX-2 inhibition in vitro. Here, PTGS2 is linked to neoplasm.